State Street’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-2,202,069
| Closed | -$10.7M | – | 3900 |
|
|
2020
Q1 | $10.7M | Buy |
2,202,069
+41,324
| +2% | +$268K | ﹤0.01% | 2242 |
|
|
2019
Q4 | $23M | Buy |
2,160,745
+151,149
| +8% | +$1.5M | ﹤0.01% | 2047 |
|
|
2019
Q3 | $20.9M | Buy |
2,009,596
+306,011
| +18% | +$4M | ﹤0.01% | 2033 |
|
|
2019
Q2 | $26.1M | Buy |
1,703,585
+61,685
| +4% | +$892K | ﹤0.01% | 1934 |
|
|
2019
Q1 | $21.1M | Buy |
1,641,900
+609,181
| +59% | +$6.89M | ﹤0.01% | 2000 |
|
|
2018
Q4 | $9.81M | Buy |
1,032,719
+133,136
| +15% | +$1.73M | ﹤0.01% | 2444 |
|
|
2018
Q3 | $14.9M | Sell |
899,583
-144,894
| -14% | -$2.32M | ﹤0.01% | 2367 |
|
|
2018
Q2 | $16.8M | Buy |
1,044,477
+149,045
| +17% | +$2.66M | ﹤0.01% | 2253 |
|
|
2018
Q1 | $13.7M | Buy |
895,432
+526,760
| +143% | +$8.21M | ﹤0.01% | 2302 |
|
|
2017
Q4 | $5.75M | Buy |
368,672
+19,087
| +5% | +$255K | ﹤0.01% | 2725 |
|
|
2017
Q3 | $3.88M | Buy |
349,585
+4,222
| +1% | +$39.7K | ﹤0.01% | 2913 |
|
|
2017
Q2 | $3.18M | Buy |
345,363
+35,116
| +11% | +$293K | ﹤0.01% | 2940 |
|
|
2017
Q1 | $2.65M | Buy |
310,247
+58,443
| +23% | +$533K | ﹤0.01% | 2984 |
|
|
2016
Q4 | $2.69M | Buy |
251,804
+21,296
| +9% | +$258K | ﹤0.01% | 2987 |
|
|
2016
Q3 | $2.49M | Buy |
230,508
+9,740
| +4% | +$79.2K | ﹤0.01% | 2886 |
|
|
2016
Q2 | $1.49M | Buy |
220,768
+4,197
| +2% | +$26.5K | ﹤0.01% | 3141 |
|
|
2016
Q1 | $1.01M | Buy |
216,571
+6,884
| +3% | +$33.6K | ﹤0.01% | 3212 |
|
|
2015
Q4 | $1.32M | Buy |
209,687
+17,913
| +9% | +$145K | ﹤0.01% | 3140 |
|
|
2015
Q3 | $1.69M | Buy |
191,774
+2,394
| +1% | +$25.1K | ﹤0.01% | 3063 |
|
|
2015
Q2 | $2.23M | Buy |
189,380
+8,150
| +4% | +$113K | ﹤0.01% | 3030 |
|
|
2015
Q1 | $2.62M | Sell |
181,230
-29
| -0% | -$444 | ﹤0.01% | 2916 |
|
|
2014
Q4 | $3.09M | Buy |
181,259
+180
| +0.1% | +$2.6K | ﹤0.01% | 2831 |
|
|
2014
Q3 | $2.25M | Buy |
181,079
+34,476
| +24% | +$424K | ﹤0.01% | 2961 |
|
|
2014
Q2 | $2.15M | Buy |
146,603
+6,479
| +5% | +$99.3K | ﹤0.01% | 3036 |
|
|
2014
Q1 | $2.85M | Sell |
140,124
-7,417
| -5% | -$180K | ﹤0.01% | 2879 |
|
|
2013
Q4 | $2.9M | Sell |
147,541
-7,218
| -5% | -$193K | ﹤0.01% | 2897 |
|
|
2013
Q3 | $7.01M | Buy |
154,759
+51,007
| +49% | +$1.66M | ﹤0.01% | 2323 |
|
|
2013
Q2 | $2.47M | Buy |
+103,752
| New | +$1.65M | ﹤0.01% | 2863 |
|
State Street's STML Position: Q2 2020 in Review
State Street sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 2,202,069 shares — an estimated $10.7M sold.
State Street first reported a position in STML in Q2 2013 and held it in 28 quarters. The position peaked at $26.1M in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- State Street reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- State Street sold 2,202,069 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $10.7M.
- State Street first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 28 quarters.
- State Street's Stemline Therapeutics, Inc. position peaked at $26.1M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on State Street's 13F filing for Q2 2020, filed 14 Aug 2020.